Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human FABP1 Antibodies:
anti-Mouse (Murine) FABP1 Antibodies:
anti-Rat (Rattus) FABP1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal FABP1 Primary Antibody for ICC, IF - ABIN4309903
Yan, Janda, Chang, Zheng, Larkin, Luca, Chia, Mah, Han, Terry, Ootani, Roelf, Lee, Yuan, Li, Bolen, Wilhelmy, Davies, Ueno, von Furstenberg, Belgrader, Ziraldo, Ordonez, Henning, Wong, Snyder et al.: Non-equivalence of Wnt and R-spondin ligands during Lgr5(+) intestinal stem-cell self-renewal. ... in Nature 2017
Show all 2 Pubmed References
Monoclonal FABP1 Primary Antibody for IHC (p), ELISA - ABIN533788
Atshaves, Storey, Huang, Schroeder: Liver fatty acid binding protein expression enhances branched-chain fatty acid metabolism. in Molecular and cellular biochemistry 2004
Show all 2 Pubmed References
Human Monoclonal FABP1 Primary Antibody for IA, FACS - ABIN2192217
Bax, Siersema, Haringsma, Kuipers, Vos, Van Dekken, Van Vliet, Kusters: High-grade dysplasia in Barrett's esophagus is associated with increased expression of calgranulin A and B. in Scandinavian journal of gastroenterology 2007
Study utilizing integrative analysis of transcriptomic, metabolomic, and clinical data propose a model of GOT2 transcriptional regulation, in which the cooperative phosphorylation of STAT3 and direct joint binding of STAT3 and p65/NF-kappaB to the proximal GOT2 promoter are important. Furthermore, high aberrant GOT2 expression is prognostic in diffuse large B-cell lymphoma.
urinary level associated with the chronic kidney disease classification in HIV-infected patients, but not associated with antiretroviral therapy and tenofovir disoproxil fumarate
Both peak oxygen consumption and grip strength were inversely associated with urinary L-FABP levels in middle-aged and older individuals without chronic kidney disease.
Nonrenal conditions and systemic severity should be considered for improved AKI prediction by NGAL and L-FABP as biomarkers.
The results of our study on this larger than 5800-patient cohort suggest beneficial effects of high B12 vitamin level, negative effects of high sodium levels or high AST (aspartate aminotransferase) liver enzyme levels to cognition.
urine L-FABP/C is permanently elevated in chronic kidney disease patients.
Our data suggests that the polymorphism in genes IL-1beta, IL-1Ra and FABP1 included in this study are not associated with PCOS development, but can influence important biochemical and metabolic parameters in PCOS.
On PICU day 1, interleukin-18 predicted acute kidney injury with area under the curve=0.82, but neutrophil gelatinase-associated lipocalin and liver fatty acid binding protein predicted acute kidney injury with area under the curve of less than or equal to 0.69; on PICU day 2, area under the curve was higher. Interleukin-18 and liver fatty acid binding protein on day 1 predicted prolonged acute kidney injury.
In total, 68 miRNAs potentially targeting FABP1 were selected; of these, miR-3941, miR-4517, and miR-4672 directly targeted the FABP1 3' untranslated region. Mimics of the three miRNAs substantially repressed FABP1 expression at translational level and led to HepG2 cell resistance to steatosis and cell injury induced by free fatty acids mixture, which rescue of FABP1 overexpression reversed.
This study demonstrated that the loss of FABP1 expression is associated with MSI carcinomas and that interferon gamma stimulation plays a role in this process via its interaction with PPARgamma.
Hepatic adenomas co-occurring with fibrolamellar carcinomas show LFABP loss and are negative for PRKACA rearrangements, indicating they are genetically distinct lesions. These data also demonstrate that LFABP loss, which characterizes HNF1-alpha inactivation, is a consistent feature of fibrolamellar carcinoma, indicating HNF1-alpha inactivation is an important event in fibrolamellar carcinoma pathogenesis.
studies indicate that FABP1 is essential for proper lipid metabolism in differentiated enterocytes, particularly concerning fatty acids uptake and its basolateral secretion.
CDH5 and FABP1 expression levels were both elevated in drug-induced liver injury.
A high resolution NMR comparative molecular analysis of L-FABP T94T and L-FABP T94A in their unbound states and in the presence of representative ligands of the fatty acid and bile acid classes showed that threonine to alanine replacement did not result in strongly perturbed structural and dynamic features, although differences in oleic acid binding by the two variants were detected.
Studies show that despite overall tertiary structure similarity, the hFABP1 differs significantly from rat FABP1 in secondary structure, much larger ligand binding cavity, and affinities/specificities for some ligands. Moreover, while both mouse and hFABP1 mediate ligand induction of PPARA, they differ markedly in genes induced. hFABP1 T94A variant is associated with altered body mass index.[review]
Like in adults, FABP seems to be associated with markers of metabolic risk in obese adolescents
analysis of structural, dynamic, and binding properties of the liver fatty acid binding protein (LFABP) in crowded solutions
Urinary L-FABP, NGAL, Kim-1 and albumin levels increased during the acute phase of kidney injury and were significantly correlated with the degree of tubulointerstitial fibrosis during the chronic phase. These markers could detect higher risk of progression to CKD.
L-FABP was found to associate with VEGFR2 on membrane rafts and subsequently activate the Akt/mTOR/P70S6K/4EBP1 and Src/FAK/cdc42 pathways, which resulted in up-regulation of VEGF-A accompanied by an increase in both angiogenic potential and migration activity. L-FABP significantly promoted tumor growth and metastasis in a xenograft mouse model.
In chronic kidney disease, high urinary L-FABP correlated with the development of end-stage renal disease and cardiovascular disease.
Thermal aggregation of aspartate aminotransferase from pig heart mitochondria (mAAT) has been studied at various temperatures and various protein concentrations by dynamic light scattering.
Ablating both Fabp1 and Scp2/Scpx (TKO) induces hepatic phospholipid and cholesterol accumulation in high fat-fed mice
role of Fabp1/Scp-2 in hepatic phytol metabolism
Individually ablating SCPx or SCP2/SCPx elicited concomitant upregulation of L-FABP.
Lack of a significant decrease in the flux of HDL-[(3)H]CE to biliary FC or bile acids in FABP1(-/-) mice indicates the likely compensation of its function by an as yet unidentified mechanism. Taken together, these studies demonstrate that FABP1 and SCP2 facilitate the preferential movement of HDL-CEs to bile for final elimination
data showed that Fabp1 gene ablation markedly diminished the impact of high-fat diet on brain endocannabinoid levels, especially in male mice
Studies show that despite overall tertiary structure similarity, the hFABP1 differs significantly from rat FABP1 in secondary structure, much larger ligand binding cavity, and affinities/specificities for some ligands. Moreover, while both mouse and hFABP1 mediate ligand induction of PPARA, they differ markedly in genes induced.
FABP1 knockout increased brain levels of arachidonic acid-containing endocannabinoids
L-FABP was more important in hepatic retention of bile acids, while SCP-2/SCP-x more broadly affected biliary bile acid and phospholipid levels.
These findings suggest that some of the phenotypic divergence between the two L-Fabp(-/-) lines may reflect unanticipated differences in genetic background, underscoring the importance of genetic background in phenotypic characterization.
Loss of L-FABP and SCP-2, or both induces hepatic lipid accumulation in female mice and mimics non-alcoholic fatty liver disease.
attenuates tubulointerstitial damage in aldosterone-induced nephropathy by reducing oxidative stress
L-FABP appears to function more in hepatic retention of bile acids as well as hepatic uptake and biliary secretion of HDL-cholesterol
L-FABP is not required to channel ATGL-hydrolyzed FAs to mitochondria for beta-oxidation or the nucleus for PPAR-alpha regulation
Data show that combined deletion of microsomal triglyceride transfer protein (Mttp) and liver fatty acid binding protein 1 (L-Fabp) are protected from lithogenic diet (LD)-induced gallstone formation.
L-Fabp has a role in modifying intestinal fatty acid composition and adenoma formation in ApcMin/+ mice
The maximum increase in LFABP expression occurs when stimulation with IL-6 and PPARalpha-ligands takes place simultaneously.
This direct comparison provides evidence that LFABP and IFABP have distinct roles in intestinal lipid metabolism; differential intracellular functions in intestine and in liver
liver-type fatty acid-binding protein in the proximal tubules may protect against angiotensin II-induced SSHT by attenuating activation of the intrarenal renin-angiotensin system and reducing oxidative stress and tubulointerstitial inflammation.
These data establish that L-FABP is an indirect antioxidant protein essential for sequestering FFA and that its impairment could contribute to in the pathogenesis of alcoholic liver disease .
combinatorial interactions between multiple regulatory factors are responsible for the gene expression of L-FABP in the liver
Glutamic-oxaloacetic transaminase is a pyridoxal phosphate-dependent enzyme which exists in cytoplasmic and inner-membrane mitochondrial forms, GOT1 and GOT2, respectively. GOT plays a role in amino acid metabolism and the urea and tricarboxylic acid cycles. The two enzymes are homodimeric and show close homology.
fatty acid-binding protein 1
, fatty acid-binding protein, liver
, liver-type fatty acid-binding protein
, aspartate aminotransferase 2
, aspartate aminotransferase, mitochondrial
, aspartate transaminase 2
, fatty acid-binding protein
, glutamate oxaloacetate transaminase 2
, glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)
, kynurenine aminotransferase 4
, kynurenine aminotransferase IV
, kynurenine--oxoglutarate transaminase 4
, kynurenine--oxoglutarate transaminase IV
, plasma membrane-associated fatty acid-binding protein
, transaminase A
, 14 kDa selenium-binding protein
, fatty acid binding protein liver
, squalene- and sterol-carrier protein
, fatty acid binding protein 1, liver
, fafatty acid binding protein 1, liver
, liver fatty acid binding protein
, fatty acid binding protein 1-A, liver
, LOW QUALITY PROTEIN: fatty acid-binding protein, liver